NRX Pharmaceuticals, Inc. (NRXP) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001719406 · SEC filings checked Oct 18, 2026
Next report
Nov 19, 2026
Estimated from reporting history (94-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$2.60
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
—
Needs four consecutive reported quarters.
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 17, 2026 | $1.1M | $-16.5M | — | Filing |
| Mar 31, 2026 | May 15, 2026 | $1.1M | $-1.4M | — | Filing |
| Dec 31, 2025 | Mar 23, 2026 | $983,000 | $361,000 | — | Filing |
| Sep 30, 2025 | Nov 14, 2025 | $242,000 | $-5.9M | — | Filing |
| Jun 30, 2025 | Aug 18, 2025 | $0 | $-17.6M | — | Filing |
| Mar 31, 2025 | May 21, 2025 | $0 | $-5.5M | — | Filing |
| Dec 31, 2024 | Mar 21, 2025 | Announced; figures arrive with the 10-Q | $-9.1M | — | Filing |
| Sep 30, 2024 | Nov 15, 2024 | $0 | $-1.6M | — | Filing |
What would NRX Pharmaceuticals, Inc. have to report for its valuation to change?
Four consecutive reported quarters of diluted EPS are not available in SEC filings. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.